Diurnal Group PLC - Cardiff-headquartered pharmaceutical company - Signs two European market and distribution agreements for paediatric adrenal insufficiency drug Alkindi and cortisol deficiency drug Chronocort. Agreements cover the distribution and marketing of Alkindi and Chronocort in the Benelux Union - consisting of Belgium, the Netherlands, and Luxemburg - as well as Alkindi in Switzerland.
The agreement for the Benelux Union is with pharmaceutical company Consilient Health. Consilient Health will receive the exclusive right to market and sell Alkindi and Chronocort in the Benelux Union in conjunction with its strategic partner, Goodlife Pharma.
Diurnal adds it has entered into an agreement for the marketing and distribution of Alkindi in Switzerland with an unnamed commercial-stage pharmaceutical company focused on prescription medications for niche and orphan indications. Under the terms of the agreement, Diurnal's partner will receive the exclusive rights to market and sell Alkindi in Switzerland and will submit the drug for marketing authorisation in Switzerland during 2020
"These two additional marketing and distribution agreements for Alkindi and additional one for Chronocort further validate the quality of our products and immediately broaden the future availability of Alkindi in Europe. Both of our new partners are well-placed to distribute our products in their respective markets, and we believe that our strategy and global ambitions are aligned with them through these collaborations," said Diurnal Chief Executive Martin Whitaker.
Current stock price: 60.00 pence
Year-to-date change: up sharply from 28.00p
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
